Dr. Angela Fleischman, Assistant Professor, Dept. of Medicine, Hematology/Oncology, UC Irvine Health Dr. Fleischman’s Bio: I am a physician-scientist dedicated to a life-long career investigating MPN, integrating my research with the clinical care of patients with this disease. My overarching goal is to identify what drives disease initiation in MPN and to ultimately translate my […]
Riggins Black Polycythemia Vera Story
Interferon use in PV – A Patient’s Perspective by Riggins Black Looking back at old CBCs, I found I “might” have had PV since 1971. By the way, this is a good reason for you all to become guardians of your medical records (no one will preserve them as well as you can). Although I’ve always […]
PV Warriors!
by Gwen Lord For the last 20 years I have lived in a place named Colchester which is known as Britain’s oldest recorded town. Original roman walls still stand and mark the boundaries of a Roman Castle that is now used as a museum and contains many artefacts found in the Colchester area. Just a […]
Nordic MPN Study Group 2013
Nordic guidelines on the diagnosis and treatment of patients with Myeloproliferative Neoplasms The Nordic study group on myeloproliferative neoplasms (NMPN) is a pan-Nordic organization that has conducted Nordic clinical trials since 2001. NMPN decided in 2006 to write new guidelines, based on already existing national guidelines from the Nordic countries, Italy1 and Great Britain.2 The first […]
ASH 2013 News on MPNs
This update is provided by the MPN Research Foundation This year’s American Society of Hematology (ASH) meeting provided a bittersweet update on the progress of JAK inhibition therapy in the MPNs. As many readers already know, the Sanofi JAK inhibitor, which had completed Phase 3 trials and was well on its way to the FDA […]
CALR Mutated Essential Thrombocythemia is a distinct disease
JAK2 or CALR mutation status defines subtypes of ET with substantially different clinical course and outcomes Key Points JAK2 (V617F) mutated essential thrombocythemia and polycythemia vera are different phenotypes in the evolution of a single neoplasm CALR mutated essential thrombocythemia is a distinct disease entity not only at molecular level but also with respect to clinical outcomes Abstract Patients with […]
Christmas Blessings
Living and Laughing through a Blood Cancer by Marielle Lanoir It is hard to believe that Christmas is this week. Three years ago I would have provided Craig with a list of items I so “desperately” needed. Probably another purse, perfume or some other vital item I had to have to get through the following […]
Support the MPN Research Foundation
Dear MPN Patient, Hello! Allow me to introduce myself – my name is Molly Guy, my dad Robert Rosen is the founder of the MPN Foundation, and I’ve been a board member for over two years. In 1998, after experiencing numbness in his fingers and toes, and endless disorienting doctor’s visits, my Dad found himself […]
MPD-RC 111 Clinical Trial for High Risk Polycythemia Vera or Essential Thrombocythemia
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses the Myeloproliferative Disorders Research Consortium (MPD-RC 111), a clinical trial investigating single arm salvage therapy with pegylated interferon alfa-2a for patients with high risk polycythemia vera or high risk essential […]
MPD-RC 112 Clinical Trial for High Risk PV and ET Patients
Randomized Clinical Trial of Pegylated Interferon alfa-2a versus Hydroxyurea Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses MPD-RC 112, a randomized trial of pegylated interferon alfa-2a versus hydroxyurea therapy in the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Key Points: Why are we doing the Study? Top […]
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- Next Page »
